Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT02844335

Combination of Cryosurgery and NK Immunotherapy for Advanced Breast Cancer

Breast Cancer Recurrent Clinical Trial

Clinical Trial Summary

The aim of this study is the safety and efficacy of cryosurgery plus NK immunotherapy to advanced breast cancer.

Clinical Trial Description

By enrolling patients with breast cancer adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of the combined therapy using cryosurgery and nature killer (NK) cells for advanced breast cancer.

The safety will be evaluated by statistics of adverse reactions. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02844335
Study type Interventional
Source Fuda Cancer Hospital, Guangzhou
Contact
Status Completed
Phase Phase 1/Phase 2
Start date July 1, 2016
Completion date July 1, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT05301530 - Clinical Trial to Assess Pharmacokinetic Parameters and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients. Phase 1
Recruiting NCT05592938 - Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE) N/A
Completed NCT04330339 - Prolonged Nightly Fasting in Breast Cancer Survivors N/A
Active, not recruiting NCT02915445 - EpCAM CAR-T for Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT05464082 - Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC Phase 2
Completed NCT05301010 - Clinical Trial to Assess Efficacy and Safety of NNG-TMAB (Trastuzumab) on Recurrent or Metastatic Breast Cancer Patients Phase 3
Recruiting NCT05730608 - 18F-FDG PET/CT Imaging for Breast Cancer N/A
Completed NCT01552655 - Breast Cancer Recurrence - the Accuracy of Dual-time PET/CT N/A
Not yet recruiting NCT05406661 - Registry of Local Recurrences After Breast-conserving Surgery
Recruiting NCT03820830 - Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer Phase 3
Completed NCT02248571 - Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab Phase 4
Recruiting NCT02947061 - S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer Phase 2